submitted on 2025-11-04, 07:55 and posted on 2025-11-04, 07:57authored byKirti S. Prabhu, Shilpa Kuttikrishnan, Zahwa Mariyam, Ummu Habeeba, Anu Jayanthi Panicker, Tariq Masoodi, Kulsoom Junejo, Shahab Uddin
<p dir="ltr">Cancer stem cells (CSCs) are a small subpopulation bearing self-renewal ability, mediating tumor initiation and propagation. Several molecular pathways, including the PI3K/AKT/mTOR pathway, are known to be aberrantly activated in cancers. In CSCs, PI3K/AKT/mTOR pathway has been associated with attribution of various properties to cancer cells including stemness characteristics, proliferation, migration, epithelial to mesenchymal transition, and autophagy. Thus, targeting PI3K/AKT/mTOR pathway with novel inhibitors might help to control the growth and proliferation of the breast CSC population. Though many studies have focused on PI3K/AKT/mTOR pathway in breast cancer, limited literature is available on the role of PI3K/AKT/mTOR pathway in breast CSCs. Here, in our present review, we have highlighted the role of the PI3K/AKT/mTOR signaling pathway in breast CSCs and its applications in therapeutic targeting.</p><h2>Other Information</h2><p dir="ltr">Published in: Naunyn-Schmiedeberg's Archives of Pharmacology<br>License: <a href="https://creativecommons.org/licenses/by/4.0" target="_blank">https://creativecommons.org/licenses/by/4.0</a><br>See article on publisher's website: <a href="https://dx.doi.org/10.1007/s00210-025-04297-3" target="_blank">https://dx.doi.org/10.1007/s00210-025-04297-3</a></p>
Funding
Open Access funding provided by the Qatar National Library.